Skip to main content


Latest articles

18-04-2019 | Diabetes | News | Article

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Diabetes | News | Article

Study highlights ‘immaturity’ of diabetes self-management apps

A large proportion of mobile apps for self-management of blood glucose do not provide real-time decision support for users with type 2 diabetes, researchers report.

17-04-2019 | Diabetes | News | Article

SONAR results support atrasentan for preserving renal function in type 2 diabetes

The endothelin receptor antagonist atrasentan may reduce the risk for kidney disease progression among certain high-risk patients with type 2 diabetes and kidney disease, indicate findings from the SONAR trial.

16-04-2019 | Diabetes | News | Article

Dapagliflozin–saxagliptin 'attractive' for type 2 diabetes with kidney disease

Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show.

15-04-2019 | Diabetes | News | Article

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

12-04-2019 | Diabetes | News | Article

Meta-analysis demonstrates benefits of add-on sotagliflozin in type 1 diabetes

Adding the SGLT1/2 inhibitor sotagliflozin to insulin treatment improves glycemic and non-glycemic outcomes among people with type 1 diabetes, but at the cost of an increased risk for diabetic ketoacidosis, researchers report in The BMJ.

11-04-2019 | Diabetes | News | Article

BANTING confirms evolocumab benefits in type 2 diabetes

The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes.

11-04-2019 | Diabetes | News | Article

EMPRISE shows real-world HF protection with empagliflozin

An interim analysis of EMPRISE shows reductions in heart failure risk with empagliflozin in real-world users that match those reported in the EMPA-REG OUTCOME trial.

10-04-2019 | Diabetes | News | Article

Existing CV disease confers high short-term vascular risk in type 2 diabetes

People with type 2 diabetes are more likely to experience cardiovascular events, particularly myocardial infarction, within 3 years of starting glucose-lowering therapy if they have pre-existing ischemic heart disease, research shows.

09-04-2019 | Diabetes | News | Article

Registry study confirms high CVD, mortality risk of early-onset type 2 diabetes

Research using the Swedish National Diabetes Registry shows that diabetes confers a particularly high relative risk for mortality and multiple cardiovascular disease outcomes in people who are young when diagnosed.

08-04-2019 | Diabetes | News | Article

Real-world benefits of flash glucose monitoring confirmed in high-risk cases

Flash glucose monitoring significantly reduces time in hyperglycemia or hypoglycemia in people with diabetes at high risk for either outcome, with the benefit sustained for at least 6 months, real-world study data show.

05-04-2019 | Diabetes | News | Article

Variable renal trajectories may complicate type 2 diabetes prescribing

People with type 2 diabetes experience an overall decline in renal function over time, but there is substantial variation among individuals, with some seeing an improvement in estimated glomerular filtration rate, researchers report.

04-04-2019 | Diabetes | News | Article

Randomized trial questions superiority of insulin pumps over injections in children

Insulin pumps and multiple daily injections deliver similar glycemic control and safety profiles when allocated alongside education and support at the point of type 1 diabetes diagnosis, say researchers.

04-04-2019 | Diabetes | News | Article

Urine analysis highlights suboptimal type 2 diabetes medication use

Objective analysis of urine samples shows that some patients with type 2 diabetes do not take their antihypertensive, antihyperlipidemic, and oral hypoglycemic medications as prescribed.

03-04-2019 | Diabetes | News | Article

Real-world data support predictive low-glucose alerts for hypoglycemia avoidance

The frequency at which people with type 1 diabetes experience hypoglycemia decreases during the first 30 days after they switch to a continuous glucose monitor that incorporates a predictive low-glucose alert, research shows.

01-04-2019 | Diabetes | News | Article

Closed-loop insulin feasible for inpatients needing nutritional support

Researchers show that closed-loop insulin delivery achieves markedly better glucose control than standard insulin management in hospitalized patients with hyperglycemia receiving enteral or parenteral nutrition.

29-03-2019 | Diabetes | News | Article

HbA1c unreliable for diabetes diagnosis in isolation

Relying solely on glycated hemoglobin to diagnose type 2 diabetes will miss a substantial proportion of cases and thus the opportunity for early intervention, say researchers.

28-03-2019 | Diabetes | News | Article

Any pregnancy dysglycemia may raise CVD risk

The association between poor glycemic control during pregnancy and subsequent risk for cardiovascular disease extends to women without gestational diabetes, study findings suggest.

27-03-2019 | Cardiovascular | News | Article

Cardiovascular autonomic neuropathy can be reversed in type 2 diabetes

Cardiovascular autonomic neuropathy is reversible in people with type 2 diabetes, report Korean researchers who found that age was the most important predictor of recovery.

26-03-2019 | Diabetes | News | Article

PIONEER 3: Oral semaglutide proves worth against sitagliptin

Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.